Four male infants with early neonatal infection caused by coxsackievirus B3 (presumed in one case) exhibited severe thrombocytopenia and liver dysfunction at presentation. The three infants who were administered human normal immunoglobulin within 3 days of disease onset survived, while the fourth infant, who received the preparation 6 days after disease onset, died.
Neonatal infection with group B coxsackievirus (CB) can be lethal. 1 Since Kaplan's review in 1983, 2 only a limited number of cases with a fatal outcome have been reported, [3] [4] [5] but it is not known whether the number of such deaths may perhaps have decreased. Although there are presently no antiviral agents for use in treating such enteroviral infections, 6 anecdotal reports suggest that intravenous infusion of large doses of immunoglobulin, which contains high titers of antibody to enteroviruses, may improve the chance of survival. [7] [8] [9] It is possible that such treatment has contributed to the decrease in the number of fatal cases of neonatal CB infection. We describe the findings and outcome in four male neonates who received this preparation for CB infection.
METHODS FOR VIRAL ISOLATION
Conventional viral isolation methods were used. 10 The cell lines used for viral propagation were vero, HEp-2, RD18s, HEL, BHK21, and MDCK. The serotype of the isolated CB was determined by the neutralizing antibody method using the vero or HEp-2 cell lines. 10 Titers of neutralizing antibodies against CB3 in the patients' sera were determined using 100 TCID 50 of CB3 (Nancy strain) as a challenge virus grown in vero or HEp-2. A significant (more than fourfold) increase in the titer of neutralizing antibody against CB3 in paired serum samples was considered positive for CB3 infection.
In addition, organs of the one nonsurviving infant obtained at autopsy were homogenated in Eagle's minimum essential medium containing 10 mg/liter gentamicin, 2.5 mg/liter amphotericin B, and 2% fetal calf serum (wet weight of organ/medium; 1/9). After centrifugation (2400g, 20 minutes), the supernatant was used for viral propagation and for the detection of the enterovirus gene by means of the reverse transcription-coupled polymerase chain reaction.
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CASE REPORTS
We observed four male Japanese neonates with CB infection, each of whom exhibited severe coagulation disorders and liver dysfunction ( Table 1 ). The four were born at three different hospitals in the eastern part of the Gunma Prefecture between July 5 and August 11, 1995. During this period, approximately 600 infants were born within a 60-km radius in this district. Each of the four patients manifested fever and poor feeding within 4 days of birth. Only one mother, that of case 2, had exhibited flu-like symptoms and complained of abdominal pain. She underwent an emergency cesarean section for a suspected premature separation of the placenta. Each infant was healthy at birth, with an Apgar score of Ն9 at 5 minutes. After the illness became manifest, the four infants were transferred to Kiryu Kosei General Hospital at the ages of 3, 5, 7, and 10 days, respectively. At presentation, each exhibited severe thrombocytopenia, prolonged activated partial thromboplastin time, and elevated serum levels of aspartate transaminase and lactate dehyrogenase. The coagulation disorder was life-threatening in all cases as evidenced by a decreased platelet count and a prolonged activated partial thromboplastin time. Three of the four infants responded to aggressive treatment, including cardiorespiratory support, the intravenous administration of immunoglobulin (freeze-dried sulfonated human normal immunoglobulin; Kaketsuken Laboratories, Kumamoto, Japan), an antithrombin III product, and transfusions of fresh-frozen plasma and/or concentrated platelet suspension ( Table 2 ). The coagulation disorder was stabilized in the three survivors within 3 to 4 days after the initiation of the immunoglobulin and other blood products. The fourth infant had been referred to us 6 days after disease onset, and despite aggressive treatment that included immunoglobulin, fresh-frozen plasma, antithrombin III, and concentrated platelet suspension with an exchange transfusion, he failed to respond and died on the 7th day after disease onset. Autopsy revealed the presence of cardiomyopathy, hepatocellular necrosis, and pulmonary hemorrhage.
Results of viral isolation studies confirmed the presence of Group B coxsackievirus serotype 3 in three of the four infants, with samples for viral isolation not available in one of the survivors (case 3). In International Perspective
that patient, the titer of neutralizing antibody to CB3 was Ͻ 8ϫ at 3 days of age, and was increased to 256ϫ by 25 days of age. The infant who died exhibited a total of 150 base pairs of the enterovirus gene in the brain, heart, spleen, and liver. Thus, the diagnosis of CB3 infection was definitive in three and presumptive in one of the four patients
DISCUSSION
Human immune serum globulin has been reported to contain neutralizing antibodies to nonpolio enteroviruses, including CB3. 6, 12 The immunoglobulin used in the present patients also contained antibody to CB3 (256ϫ by the neutralizing method). It is possible that its early administration within 3 days of disease onset may have helped to save the lives of three of the infants, although we can not confirm this possibility. The one infant who died of the infection had received immunoglobulin starting at a relatively later time, i.e., 6 days after disease onset.
Samples for viral isolation were not available in one survivor (case 3). Because his titer of neutralizing antibody to CB3 was evaluated and found to be increased only after he had received immunoglobulin, this elevation could not be interpreted. Therefore, the diagnosis of CB3 infection remained presumptive. However, his laboratory data and clinical findings resembled those of the other survivors.
These four patients serve to emphasize the point that serious outbreaks of CB infection can still occur in neonates, and can prove fatal. The presence of a severe coagulation disorder together with liver dysfunction in a neonate may suggest the possibility of a CB or an echovirus infection. 13, 14 The administration of normal human immu- noglobulin-containing antibody to echovirus to exposed newborns has been reported to prevent an echovirus infection. 7, 8 Thus, the immediate administration of immunoglobulin to neonates with the characteristic signs and symptoms of CB or echovirus infection, even before the causal agent has been identified, may prove life-saving.
